 |
- In December 2020, Pfizer selected antibodies directed at a previously-selected target under the cancer immunotherapy research collaboration.
- BioInvent is eligible for potential future development milestones in excess of USD 100 million if an antibody is developed through to commercialization, as well as up to double digit royalties.
|
 |
- Co-developing (50/50 split of costs and profits) of oncolytic virus candidates for solid tumors, leveraging BioInvent’s n-CoDeR® and F.I.R.S.T™ platforms.
- Sharing of technology platforms, knowledge, and expertise.
|
 |
- Clinical trial collaboration and supply agreement with Merck, to evaluate the combination of BI-1206 and KEYTRUDA®
- Exclusive licensing agreement with CASI Pharmaceuticals for BI-1206 in mainland China, Taiwan, Hong Kong and Macau
|
 |
- Antibody discovery partnerships
|
 |
|